论文部分内容阅读
目的:评价卡培他滨节拍化疗联合塞来昔布治疗晚期结直肠癌的临床疗效和不良反应。方法:对51例晚期结直肠癌患者应用卡培他滨节拍化疗联合塞来昔布治疗。卡培他滨500 mg,2次.d-1,塞来昔布胶囊400 mg,2次.d-1,4周为1个周期。患者至少完成2个周期,中位治疗周期数为4.8个。结果:51例患者无一例完全缓解,9例(17.6%)部分缓解,19例(37.3%)疾病稳定;疾病控制率为54.9%(28/51)。中位疾病进展时间为5.1个月,中位总生存时间为8.4个月。主要不良反应为骨髓抑制、胃肠道反应及手足综合征,大多为Ⅰ～Ⅱ度。结论:卡培他滨节拍化疗联合塞来昔布治疗晚期结直肠癌能够有效控制疾病进展,其不良反应较小,患者可耐受。
Objective: To evaluate the curative effect and adverse reactions of capecitabine combined with celecoxib in the treatment of advanced colorectal cancer. Methods: Fifty-one patients with advanced colorectal cancer were treated with capecitabine combined with celecoxib. Capecitabine 500 mg, 2 times .d-1, celecoxib capsules 400 mg, 2 times.d-1, 4 weeks for a cycle. The patient completed at least 2 cycles and the median number of cycles was 4.8. Results: None of the 51 patients was completely relieved. Nine patients (17.6%) were partially relieved. Nineteen patients (37.3%) were stable and the disease control rate was 54.9% (28/51). The median progression time was 5.1 months and the median overall survival time was 8.4 months. The main adverse reactions were myelosuppression, gastrointestinal reactions and hand-foot syndrome, mostly Ⅰ ~ Ⅱ degrees. CONCLUSIONS: Capecitabine beating chemotherapy combined with celecoxib in the treatment of advanced colorectal cancer can effectively control the progression of the disease with less adverse reactions and is tolerable in patients.